In vitro activity does not always correlate with clinical efficacy.
*Efficacy has been demonstrated in CAP clinical studies against the following pathogens that were susceptible to ceftaroline in vitro: S. pneumoniae, S. aureus (methicillin-susceptible strains only), E. coli, H. influenzae, H. parainfluenzae and K. pneumoniae.
Efficacy has been demonstrated in clinical studies of cSSTI against pathogens that were susceptible to ceftaroline in vitro.^1
†Refers to the dosing of adults with ceftaroline q12h using 1-hour infusions.^1
‡Refers to the dosing of adults with ceftaroline q8h using 2-hour infusions to treat cSSTI. S. aureus with ceftaroline MICs ≥4 mg/mL are rare. PK/PD analyses suggest that dosing of adults with ceftaroline q8h using 2-hour infusions may treat cSSTI due to S. aureus for which ceftaroline MIC is 4 mg/mL.^1
§Available clinical data cannot substantiate efficacy against PNSP. In vitro data indicate that the following atypical species are not susceptible to ceftaroline: Chlamydophila spp., Legionella spp., Mycoplasma spp., Proteus spp. and P. aeruginosa.^1
¶Inferred by susceptibility to benzylpenicillin.⁴

CAP, community-acquired pneumonia; CE, clinically evaluable; CI, confidence interval; cSSTI, complicated skin and soft tissue infection; EOT, end of treatment; FOCUS, ceFtarOline Community-acquired pneUmonia trial vS ceftriaxone in hospitalized patients; ITT, intent-to-treat; IV, intravenous; LFU, late follow-up; ME, microbiologically evaluable; MITT, modified intent-to-treat; MITTE, modified intent-to-treat efficacy; mMITT, microbiologically modified intent-to-treat; PORT, Pneumonia Patient Outcomes Research Team; q8h, every 8 hours; q12h, every 12 hours.